Clinical trial

Precision Lifestyle Medicine Program for IFHAS Participants

Recruiting now · Not applicable · 1 countries · Registry ID NCT07742917

Recruiting nowNot applicableInterventional

What this study is about

The goal of this clinical trial is to evaluate whether a precision lifestyle medicine intervention can improve cardiometabolic health in Emirati adults aged 25 to 50 years living in Abu Dhabi with obesity (BMI 30-35 kg/m²) who have previously completed IFHAS screening. The study will also use IFHAS screening data to better understand participants' health profiles and the relationship between lifestyle factors and chronic diseases. The main questions it aims to answer are: * Does a precision lifestyle medicine program improve cardiometabolic biomarkers after an 18-week intervention? * Can IFHAS screening data be used to identify health risk profiles and support personalized lifestyle interventions for the Emirati population? Researchers will compare participants receiving the precision lifestyle medicine intervention with a propensity-matched control group receiving standard IFHAS care to determine whether the intervention leads to greater improvements in cardiometabolic health. Participants will: * Take part in an 18-week personalized lifestyle medicine program tailored to their health profile. * Attend study visits and complete health assessments over a total study period of 24 weeks. * Undergo cardiometabolic biomarker assessments before and after the intervention. * Complete questionnaires or assessments about their adherence to the lifestyle program and their experience with the precision lifestyle medicine clinic. * Provide biological samples to support the establishment of a biomarker repository for future research.

A promising-looking record is not the same as confirmed eligibility. The study team must review the full criteria and current recruitment status.

Basic eligibility

Age25 Years to 50 Years

SexAll

Healthy volunteersNot accepted

ConditionObese Adults, BMI/Body Composition, Cardiometabolic Risk, Cardiovascular Disease Risk, Type 2 Diabetes Risk

Full registry criteria

Inclusion Criteria: * Emiratis residing in Abu Dhabi emirate * Aged 25-50 years * BMI 30-35 kg/m² * Thiqa cardholder * Previous participation in IFHAS screening * Able to provide informed consent * Participant in the Emirati Genome Programme * No weight-loss medications (e.g., Ozempic, Saxenda, Wegovy) within 3 months of enrollment. Exclusion Criteria: * Aged under 25 years or over 50 years of age * BMI range under 30 kg/m2 and over 35 kg/m2 * Taking weight loss medication such as GLP-1 drugs (Ozempic, Saxenda, Wegovy) * Active treatment for serious medical conditions (cancer, planned surgery, immunomodulation) * Transplant surgery within 12 months * Pregnancy * Surgery within 3 months prior to recruitment * Physical limitations preventing exercise participation * Current enrolment in other lifestyle intervention programs * Active psychiatric conditions, cognitive impairment, or mental health conditions affecting study participation * Contraindication to MRI or DEXA imaging, including severe claustrophobia or need for sedation.

Treatments and study arms

Precision Lifestyle Medicine Program

Behavioral

Participants receive an 18-week precision lifestyle medicine intervention based on individual IFHAS screening results and cardiometabolic risk stratification. The program includes personalized lifestyle recommendations and multidisciplinary clinical support focused on improving cardiometabolic health. Participants are followed for 24 weeks, with assessments conducted at baseline and post-intervention.

Standard IFHAS Care

Other

Participants receive standard IFHAS care without participation in the precision lifestyle medicine intervention. This group serves as a propensity score-matched comparison cohort.

Primary outcomes

Change in Body Mass Index (BMI)Baseline and Week 24

Mean change in body mass index (BMI) from baseline to Week 24 following the precision lifestyle medicine intervention.

Change in Cardiometabolic Composite Response24 weeks

Proportion of participants classified as cardiometabolic responders at Week 24, defined as achieving at least two of the following: ≥3% reduction in body weight, ≥5% reduction in ApoB (or LDL-C), ≥0.3% reduction in HbA1c (or ≥15% reduction in HOMA-IR), ≥3 mmHg reduction in systolic blood pressure, or ≥2 cm reduction in waist circumference.

Study locations

1 locations were listed when this page was built. The first 40 are shown.

Institute for Healthier Living🇦🇪 Abu Dhabi, United Arab Emirates

Open map

Shamma Al JneibiContact

Email · Call 026451700